Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muraglitazar + Glyburide in Type 2 Diabetes
NCT00162175Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2003
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of muraglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change from Baseline in Glycosylated Hemoglobin A1c at 24 weeks. Started Jul 2003; status: completed.
02
Drugs
muraglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00162175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162175.